Nicolet Advisory Services LLC Purchases 4,844 Shares of Bristol-Myers Squibb (NYSE:BMY)

Nicolet Advisory Services LLC raised its stake in Bristol-Myers Squibb (NYSE:BMY) by 62.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,600 shares of the biopharmaceutical company’s stock after purchasing an additional 4,844 shares during the period. Nicolet Advisory Services LLC’s holdings in Bristol-Myers Squibb were worth $650,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Westside Investment Management Inc. boosted its holdings in shares of Bristol-Myers Squibb by 2.9% in the fourth quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company’s stock worth $367,000 after buying an additional 204 shares during the last quarter. Traynor Capital Management Inc. boosted its stake in shares of Bristol-Myers Squibb by 2.8% during the first quarter. Traynor Capital Management Inc. now owns 7,672 shares of the biopharmaceutical company’s stock valued at $416,000 after purchasing an additional 207 shares during the period. Fulton Breakefield Broenniman LLC boosted its stake in shares of Bristol-Myers Squibb by 4.6% during the fourth quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 209 shares during the period. Accurate Wealth Management LLC boosted its stake in shares of Bristol-Myers Squibb by 4.0% during the first quarter. Accurate Wealth Management LLC now owns 5,612 shares of the biopharmaceutical company’s stock valued at $304,000 after purchasing an additional 216 shares during the period. Finally, Newbridge Financial Services Group Inc. boosted its stake in shares of Bristol-Myers Squibb by 12.8% during the first quarter. Newbridge Financial Services Group Inc. now owns 1,910 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 216 shares during the period. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Stock Up 0.6 %

Shares of Bristol-Myers Squibb stock traded up $0.25 on Friday, reaching $42.64. 12,839,934 shares of the company were exchanged, compared to its average volume of 16,336,650. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $65.38. The company has a market cap of $86.44 billion, a P/E ratio of -13.75, a price-to-earnings-growth ratio of 15.55 and a beta of 0.44. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The stock’s 50 day moving average price is $41.68 and its 200-day moving average price is $47.02.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the prior year, the company posted $2.05 earnings per share. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. As a group, equities analysts forecast that Bristol-Myers Squibb will post 0.55 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.63%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BMY shares. BMO Capital Markets lowered their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. Barclays reduced their price target on shares of Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 10th. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 27th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Finally, Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $59.07.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.